Saikosaponin C

Pharmacology & Research

Saikosaponin C is a minor oleanane triterpenoid saponin of Bupleurum (Chai Hu) root, and one of the three principal saikosaponins (a, c, d). Its honest distinction is that it has two genuinely molecule-specific signals that differ from its siblings: an anti-HBV effect (with low cytotoxicity, unlike other saikosaponins) and a pro-angiogenic endothelial effect (whereas saikosaponin a suppresses angiogenesis). By contrast, Chai Hu’s anti-inflammatory/hepatoprotective/anticancer reputation is class- or whole-herb-level (saikosaponin a/d and the formula), not demonstrated for saikosaponin C. There are no human trials of the isolate, and clinical use of Bupleurum is the whole herb/formula (e.g. Xiao Chai Hu Tang / Sho-saiko-to).

1. Antiviral (anti-HBV)

Saikosaponin C’s flagship and most molecule-specific result. It was first isolated as an anti-HBV saikosaponin without the cytotoxicity of its siblings ^{1Reference 1Chiang LC et al. · 2003Cytotoxicity and anti-hepatitis-B-virus activities of saikosaponins from Bupleurum speciesView study →}; later work localised the mechanism to downregulation of the hepatic transcription factors HNF1α/HNF4α, suppressing HBV pregenomic-RNA synthesis (↓ HBeAg, ↓ HBV-DNA) ^{2Reference 22019Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesisView study →}, with additive/synergistic effect alongside the nucleoside analogue telbivudine ^{3Reference 32020Combination of saikosaponin C and telbivudine synergistically enhances anti-HBV activityView study →}.

Gap: entirely in-vitro (HepG2.2.15 cell model), with no animal efficacy and no human data — a laboratory signal, not a therapy, and the effective concentrations are unlikely to be reached from oral herb intake ^{1,2Reference 1Chiang LC et al. · 2003Cytotoxicity and anti-hepatitis-B-virus activities of saikosaponins from Bupleurum speciesView study →Reference 22019Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesisView study →}.

2. Pro-angiogenic / endothelial

In a single HUVEC study, saikosaponin C induced endothelial proliferation, migration and capillary-tube formation via MMP-2, VEGF and p42/p44 MAPK (ERK) ^{4Reference 4Shyu KG et al. · 2004Saikosaponin C induces endothelial-cell growth, migration and capillary-tube formationView study →} — genuinely SSc-specific and mechanistically distinct from saikosaponin a, which blocks VEGFR2-driven angiogenesis.

Gap: a single in-vitro study in one cell type, with no in-vivo confirmation, and the direction of benefit is context-dependent — potentially relevant to wound healing/tissue repair but a caution in oncology, since tumours depend on angiogenesis ^{4Reference 4Shyu KG et al. · 2004Saikosaponin C induces endothelial-cell growth, migration and capillary-tube formationView study →}.

3. Anti-inflammatory / hepatoprotective (class)

Chai Hu’s traditional “harmonising/liver” use and its anti-inflammatory (NF-κB/iNOS/COX-2) and hepatoprotective (CCl₄) data belong to saikosaponin a/d and the whole herb/formula, not to saikosaponin C ^{5Reference 5Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}.

Gap: no saikosaponin-C-specific anti-inflammatory or hepatoprotective study exists — this is guilt-by-class, and Bupleurum’s clinical use is the whole herb/formula, never the isolate ^{5Reference 5Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
HNF1α / HNF4α (hepatic transcription factors)	downregulated → ↓ HBV pregenomic-RNA synthesis	anti-HBV (SSc-specific)
HBV replication (HepG2.2.15)	↓ HBeAg, ↓ HBV-DNA; synergy with telbivudine	anti-HBV (SSc-specific)
MMP-2, VEGF, p42/p44 MAPK (ERK)	induced → endothelial growth, migration, tube formation	pro-angiogenesis (SSc-specific)
NF-κB / iNOS / COX-2 (class)	suppressed (saikosaponin a; not shown for SSc)	anti-inflammatory — class only

Pharmacokinetics

Saikosaponin C is a large oleanane bisdesmoside saponin, with the expected class liabilities: poor passive membrane permeability, extensive gut/acid hydrolysis and low oral bioavailability. It is measurable in rat plasma by LC-MS/MS after dosing of Bupleurum preparations, confirming that some intact SSc is absorbed but at low levels ^{6Reference 62019AnimalA reliable LC-MS/MS method for the quantification of five bioactive saponins of crude and processed Bupleurum scorzonerifolium in rat plasmaView study →}; no dedicated single-compound oral-bioavailability or human pharmacokinetic study exists, so parameters are inferred from the class. The practical implication is that the in-vitro anti-HBV concentrations are unlikely to be reached from oral herb intake.

Clinical trials

There are no human trials of isolated saikosaponin C. All Bupleurum clinical experience is with the whole herb or multi-herb formula (e.g. Xiao Chai Hu Tang / Sho-saiko-to), which cannot be attributed to this saponin.

Last checked: July 2026.

Toxicity & Safety

Saikosaponin C carries a [low] flag for the specific molecule — the foundational isolation study separated it as anti-HBV with low cytotoxicity, in contrast to more cytotoxic saikosaponins ^{1Reference 1Chiang LC et al. · 2003Cytotoxicity and anti-hepatitis-B-virus activities of saikosaponins from Bupleurum speciesView study →}, and no SERCA-inhibition/cardiotoxicity or hepatotoxicity signal is attributed specifically to SSc (those belong to saikosaponin a and d) ^{7Reference 72017Content decline of the SERCA inhibitors saikosaponin a and d attenuates cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}. But the class/whole-herb caveat must not be buried: saikosaponins as a class can be hepatotoxic (saikosaponin d is a documented dose-dependent hepatotoxin), Bupleurum-containing formulas (Sho-saiko-to) carry well-known interstitial-pneumonia and hepatotoxicity reports in the formula context, and saponins are inherently haemolytic at high concentration — saikosaponin C is the mild sibling, but it travels in toxic company. Its pro-angiogenic activity ^{4Reference 4Shyu KG et al. · 2004Saikosaponin C induces endothelial-cell growth, migration and capillary-tube formationView study →} is a further theoretical caution in cancer/proliferative-retinopathy settings.

Pregnancy & lactation

Avoid. Bupleurum is traditionally reserved to formula use and not recommended in pregnancy; the saikosaponin class includes phytoestrogenic/cytotoxic members, and there are no reproductive-safety data for saikosaponin C.

Dosage

There is no established or safe human dose — saikosaponin C has never been dosed as an isolate in humans, and all figures in the literature are in-vitro (µM) or animal-plasma research concentrations, not recommendations. Any real-world exposure is as a minor fraction of whole Chai Hu root/formula.

References